首页> 中文期刊> 《肿瘤学与转化医学(英文)》 >Development of a redox-related prognostic signature for predicting biochemical-recurrence-free survival of prostate cancer

Development of a redox-related prognostic signature for predicting biochemical-recurrence-free survival of prostate cancer

         

摘要

Objective Prostate cancer(PCa)is one of the most common malignancies among elderly males.However,effective prognostic biomarkers are currently lacking.Bioinformatic analysis was used to identify patients at high risk of biochemical recurrence(BCR).Methods In our study,RNA sequencing and clinical data were downloaded from The Cancer Genome Atlas(TCGA)dataset to serve as the training and internal validation sets.The GSE84042 dataset was used as the external validation set.Batch effects were removed and normalized for the two datasets using“sva”package.Univariate Cox,least absolute shrinkage and selection operator(LASSO)Cox,and multivariate Cox regression analyses were successively performed to identify the redox-related gene(RRG)signature.After performing univariate Cox,LASSO Cox,and multivariate Cox regression analyses,a signature consisting of seven RRGs was established to predict BCR of patients with PCa,which included TP53,ADH5,SRRT,SLC24A2,COL1A1,CSF3R,and TEX19.Kaplan-Meier and receiver operating characteristic curve analyses showed good performance for the prognostic signature in the training and validation datasets.Results Univariate and multivariate Cox analyses showed that the RRG signature was an independent prognostic factor for BCR of patients with PCa.Thereafter,the nomogram results revealed that it was able to predict BCR of patients with PCa with high efficiency.Conclusion This study identified an independent prognostic signature and established a nomogram to predict BCR in PCa.This signature can be used to identify patients with PCa with a high risk of BCR,and personalized treatment can be applied.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
  • 1. PROSTATE CANCER GEN. [P] . 外国专利: ES2190925T3 . 2003-09-01

    机译:prostate cancer gen.

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号